Co-Occurring Psychiatric Disorders
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
Co-Occurring Psychiatric Disorders
Recorded: Thursday, September 29, 2022 - Saturday, October 1, 2022
On-Demand Session
Overview
This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores new research in preventing, screening, and treating psychiatric disorders among people with substance use disorders. Topics include suicide, methamphetamine psychosis, ADHD, depression, and anxiety.
There is a high prevalence of psychiatric comorbidity among people with substance use disorders, with some studies showing as high as 80% having another mental health condition. This 1-hour, 45-minute, on-demand session from the 2022 ASAM State of the Art Course explores new research in preventing, screening, and treating psychiatric disorders among people with substance use disorders. Topics include suicide, methamphetamine psychosis, ADHD, depression, and anxiety. Following the session, a moderated panel discussion among the presenters answers audience questions.
This session is comprised of 4 presentations that deep dive into different aspects of the overall topic.
- Addiction, Overdose, Suicide & the Gray Areas in Between
About 50,000 people die each year in the USA from Suicide and another 70,000 die from Overdoses, ( 50,000 from opioids). This presentation with review data and interactions about Suicide and Overdose, including clinical presentations and possible interventions which may affect either or both problems. Clinical screening methods for suicide have been developed and tested over many years and include both clinical and demographic issues. The role of substance use disorders has not previously been fully appreciated as a major risk factor, nor intervention in substance use disorders fully appreciated as a possible suicide intervention. - Over-amped: Managing Methamphetamine Use Disorder and Methamphetamine Psychosis
Methamphetamine is among the common substances of abuse related to emergency service utilization; psychosis due to methamphetamine use may be mistaken for primary psychiatric illness but in fact requires quite different treatment. Early recognition and appropriate intervention is critical. This talk reviews the epidemiology of methamphetamine use in emergency settings and describes original data of a novel intervention for treating methamphetamine-induced psychosis. A structured, emergency department-initiated intervention illustrates core elements of engaging patients presenting with methamphetamine psychosis. - Treatment of ADHD and Substance Use Disorders
Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUD) are highly comorbid, with 15-20% of treatment-seekers for SUD having current ADHD. Individuals with SUD and ADHD are more likely to relapse and less likely to be retained in treatment than those without ADHD. To date, treatment trials targeting individuals with ADHD and SUD have produced mixed results. Data from 2 studies found that among adults with ADHD and stimulant use disorder, robust dosing produced clinically meaningful therapeutic effects on the ADHD symptoms and illicit stimulant use. However, prescribing prescription stimulants needs to be done carefully to mitigate the risks of nonmedical use and diversion. Pillars of safe prescribing include accurate diagnosis, clear and defined target outcomes and careful monitoring for misuse. - Depression and Anxiety in Patients with Addiction
Co-occurring mood and anxiety disorders are highly prevalent among patients with substance use disorders, and if left untreated, they usually have a negative impact on addiction recovery. This session will review pharmacologic treatments for mood and anxiety disorders in the context of different substance use disorders (SUD). Principles of assessment and diagnosis will be presented since it is frequently unclear as to the source of mood and anxiety symptoms in the context of SUD that may be substance-induced and may or may not reach disorder-level severity or threshold. Then, when appropriate, stepped treatment strategies will be discussed.
These sessions are intended for experienced learners and are taught an intermediate or advanced level. The target audience includes:
- Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
- Physicians and other healthcare professionals who treat patients with addiction and seek an advanced level of knowledge
- Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine
This conference addresses all 6 ACGME Competencies.
Learning Objectives
At the end of the course, learners should be able to:
- Discuss the important, new, scientific breakthroughs in the prevention, diagnosis, and treatment of addiction.
- Critically evaluate new science and describe how it changes the current understanding of addiction and co-occurring medical or psychiatric disorders.
- Develop practical applications for integrating new and emerging science into practice.
- Identify gaps in the field of addiction medicine that future research can address.
- Create a network of colleagues and resources to support the learner's practice or form future research collaborations.
Registration Rates
| ASAM Learner Type | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to Education@ASAM.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or eLearning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Deadline: 10/1/2025
Instructions
- Click on the Contents tab to begin this activity.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer eSSENTIAL Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
.jpg "Speaker image")
Michael Fingerhood, MD, FACP, DFASAM (Moderator)
Associate Professor of Medicine and Public Health
Johns Hopkins University
Dr. Michael Fingerhood is an Associate Professor of Medicine and Public Health at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance use disorder treatment with primary medical care, including care for HIV and hepatitis C.
No Relevant Financial Disclosures
Richard K. Ries
MD, DFASAM
Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident.
Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health.
He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT). He is senior editor of the key reference text: Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the field of Addictions.
No Relevant Financial Disclosures
Scott Simpson
MD, MPH
Scott Simpson MD MPH is Medical Director of Psychiatric Emergency Services at Denver Health Medical Center and Assistant Professor of Psychiatry at the University of Colorado School of Medicine. Dr. Simpson has published on the management of substance use disorders in the emergency setting and part of the Denver Health team that launched Colorado's first 24/7 buprenorphine induction program. Dr. Simpson is board certified in general psychiatry, addiction medicine, and consultation-liaison psychiatry.
Does Disclose: Royalties from Taylor & Francis for a clinical textbook unrelated to presentation content
Margaret Chaplin, MD
Psychiatrist
Farrell Treatment Center, New Britain, CT Community Faculty, Department of Psychiatry, University of Connecticut Medical School, Farmington CT
Dr. Margaret Chaplin, MD currently serves as Psychiatric Consultant to the Farrell Treatment Center in New Britain, CT. She is also on the Community Faculty of the Department of Psychiatry at UConn Health and a Principal Psychiatrist for the Capital Region Mental Health Center a
Connecticut Department of Mental Health and Addiction Serivces Community Mental Health Center. She recieved her undergraduate education at Swarthmore College, her medical degree at Harvard Medical School and completed residency in psychiatry at University of Massachusetts Medical School. She is board certified in Psychiatry and Addiction Medicine and is a Mentor for the SAMSHA Provider Clinical Support System for the treatment of Opioid Use Disorder. Her area of interest is Comorbidity of SUD and Mental Health particularily with respect to Anxiety, ADHD and Insomnia.
No Relevant Financial Disclosures
Richard Rosenthal, MA, MD
Professor of Psychiatry
Renaissance School of Medicine at Stony Brook
Richard Rosenthal, MA, MD is Professor of Psychiatry and was the Inaugural Director of Addiction Psychiatry at Stony Brook School of Medicine. His research has focused on evaluating and treating mentally ill patients with co-occurring addictive disorders and novel treatments for SUD. More recently he has developed his interest in medical informatics and machine learning strategies regarding identification and impact of non-medical opioid use. He has been active in research, education, program development, treatment and public policy related to addiction. Since 2003, he has held the chair of Public Policy at the American Academy of Addiction Psychiatry.
Dr. Rosenthal received his MD at SUNY Downstate Medical Center and completed his psychiatry residency as Chief Resident at Mount Sinai Hospital. He later founded the Addiction Psychiatry program at Beth Israel Medical Center, NY, and directed one of the first ACGME-approved Addiction Psychiatry Fellowships in the US. As Chairman of Psychiatry at St. Luke’s Roosevelt Hospital Center (2001- 2014), he was Arthur J. Antenucci Professor of Psychiatry and Senior Associate Dean at Columbia University College of Physicians & Surgeons. He also served as Physician-in-Chief of the Behavioral Health Service Line of Continuum Health Partners until its 2013 merger with the Mount Sinai Health System.
Dr. Rosenthal has served as president of the American Academy of Addiction Psychiatry and the American Association for Technology in Psychiatry. He is a Distinguished Life Fellow of the American Psychiatric Association, and a Distinguished Fellow of the American Academy of Addiction Psychiatry. Author of numerous articles, book chapters and books, he is also an Editor of the American Society of Addiction Medicine Principles of Addiction Medicine. In 2008, Dr. Rosenthal was the recipient of the Founders’ Award from the American Academy of Addiction Psychiatry. He has been selected for Castle Connolly America’s Top Doctors™ since 2008.
Does Disclose: SOLVD Health, consulting payments, medical advisory panel, genetic testing for risk of developing opioid use disorder.
CME, CE, CEU and Other Credit Types
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
NAADAC, the Association for Addiction Professionals
This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1222
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1222
Continuing Education Credits (CEUs)
Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.
Maintenance of Certification (MOC) / Continuing Certification Program (CCP)
The ASAM State of the Art Course meets the CME requirements for the following primary boards:
• American Board of Medical Specialties (ABMS)
• American Board of Preventive Medicine (ABPM)
• American Board of Anesthesiology (ABA)
• American Board of Pediatrics (ABP)
• American Board of Internal Medicine (ABIM)
• American Board of Surgery (ABS)
• American Board of Psychiatry and Neurology (ABPN)
• American Board of Addiction Medicine (ABAM)
• Royal College of Physicians and Surgeons of Canada (RCPSC
Disclosure Information
In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include mitigating all possible relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee member and Presenters have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
Key:
Complete
Next
Failed
Available
Locked